FibroBiologics, Inc. (FBLG) stock
FBLGNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.90−0.02 (-2.56%)
Close on Nov 16, 2026Market cap $6.02MP/E –Yield –
FibroBiologics r&d expenses
Research and development expenses are spending on new products and technology.
FibroBiologics's R&D Expenses for the twelve months ending Jun 30, 2026 was $8.20M, up 28.3% year over year. For fiscal 2025 it was $7.41M, up 64.5% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.41M | +64.5% |
| FY2024 | Dec 31, 2024 | $4.50M | +90.2% |
| FY2023 | Dec 31, 2023 | $2.37M | +106.5% |
| FY2022 | Dec 31, 2022 | $1.15M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.66M | -18.8% |
| Q1 FY2026 | Mar 31, 2026 | $2.95M | +65.9% |
| Q4 FY2025 | Dec 31, 2025 | $797.00K | -41.2% |
| Q3 FY2025 | Sep 30, 2025 | $2.79M | +129.9% |
| Q2 FY2025 | Jun 30, 2025 | $2.04M | +109.3% |
| Q1 FY2025 | Mar 31, 2025 | $1.78M | +85.4% |
| Q4 FY2024 | Dec 31, 2024 | $1.36M | +75.4% |
| Q3 FY2024 | Sep 30, 2024 | $1.21M | +112.4% |
| Q2 FY2024 | Jun 30, 2024 | $975.00K | +78.2% |
| Q1 FY2024 | Mar 31, 2024 | $960.00K | +100.8% |
| Q4 FY2023 | Dec 31, 2023 | $773.00K | – |
| Q3 FY2023 | Sep 30, 2023 | $571.00K | – |
| Q2 FY2023 | Jun 30, 2023 | $547.00K | – |
| Q1 FY2023 | Mar 31, 2023 | $478.00K | – |
See a number that looks wrong?